RecruitingNot ApplicableNCT06382051

Modifying PEST for Psoriatic Arthritis Screening

A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")

Sponsor

Novartis Pharmaceuticals

Enrollment

502 participants

Start Date

Jan 23, 2025

Study Type

INTERVENTIONAL

Conditions

Psoriatic Arthritis Plaque Psoriasis

Summary

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying PEST Screening group for people with plaque psoriasis and psoriatic arthritis. The study is currently recruiting participants at 29 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPEST Screening group

PEST Screening group

Locations(29)

Novartis Investigative Site

Calgary, Alberta, Canada

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

Kelowna, British Columbia, Canada

Novartis Investigative Site

Surrey, British Columbia, Canada

Novartis Investigative Site

Winnipeg, Manitoba, Canada

Novartis Investigative Site

Fredericton, New Brunswick, Canada

Novartis Investigative Site

Barrie, Ontario, Canada

Novartis Investigative Site

Greater Sudbury, Ontario, Canada

Novartis Investigative Site

Hamilton, Ontario, Canada

Novartis Investigative Site

Hamilton, Ontario, Canada

Novartis Investigative Site

Hamilton, Ontario, Canada

Novartis Investigative Site

London, Ontario, Canada

Novartis Investigative Site

London, Ontario, Canada

Novartis Investigative Site

Markham, Ontario, Canada

Novartis Investigative Site

North York, Ontario, Canada

Novartis Investigative Site

Richmond Hill, Ontario, Canada

Novartis Investigative Site

Stoney Creek, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Waterloo, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Québec, Quebec, Canada

Novartis Investigative Site

Québec, Quebec, Canada

Novartis Investigative Site

Ste-Foy, Quebec, Canada

Novartis Investigative Site

Verdun, Quebec, Canada

Novartis Investigative Site

Saskatoon, Saskatchewan, Canada

Novartis Investigative Site

Saskatoon, Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06382051

Related Trials

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453127 locations

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT0728605816 locations

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT0725080240 locations

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967383 locations